NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$31.3b

Last Updated

2021/04/13 22:40 UTC

Data Sources

Company Financials +

Executive Summary

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More Details


Snowflake Analysis

Mediocre balance sheet with questionable track record.


Similar Companies

Share Price & News

How has BioNTech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BNTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: BNTX's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

10.7%

BNTX

-1.2%

US Biotechs

1.3%

US Market


1 Year Return

211.4%

BNTX

26.8%

US Biotechs

53.9%

US Market

Return vs Industry: BNTX exceeded the US Biotechs industry which returned 26.8% over the past year.

Return vs Market: BNTX exceeded the US Market which returned 53.9% over the past year.


Shareholder returns

BNTXIndustryMarket
7 Day10.7%-1.2%1.3%
30 Day25.5%-3.7%2.8%
90 Day26.3%-6.3%6.6%
1 Year211.4%211.4%28.5%26.8%56.6%53.9%
3 Yearn/a25.1%19.3%62.7%52.3%
5 Yearn/a42.7%31.9%120.5%95.9%

Long-Term Price Volatility Vs. Market

How volatile is BioNTech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioNTech undervalued compared to its fair value and its price relative to the market?

1683.41x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BNTX ($129.64) is trading above our estimate of fair value ($51.16)

Significantly Below Fair Value: BNTX is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BNTX is poor value based on its PE Ratio (1683.4x) compared to the US Biotechs industry average (30.1x).

PE vs Market: BNTX is poor value based on its PE Ratio (1683.4x) compared to the US market (22.3x).


Price to Earnings Growth Ratio

PEG Ratio: BNTX is poor value based on its PEG Ratio (1906.8x)


Price to Book Ratio

PB vs Industry: BNTX is overvalued based on its PB Ratio (19.1x) compared to the US Biotechs industry average (3.7x).


Future Growth

How is BioNTech forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

0.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BNTX's forecast earnings growth (0.9% per year) is below the savings rate (2%).

Earnings vs Market: BNTX's earnings (0.9% per year) are forecast to grow slower than the US market (18.5% per year).

High Growth Earnings: BNTX's earnings are forecast to grow, but not significantly.

Revenue vs Market: BNTX's revenue (8.8% per year) is forecast to grow slower than the US market (9.9% per year).

High Growth Revenue: BNTX's revenue (8.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BNTX's Return on Equity is forecast to be low in 3 years time (8.8%).


Past Performance

How has BioNTech performed over the past 5 years?

344.1%

Last years revenue growth


Earnings and Revenue History

Quality Earnings: BNTX has a large one-off gain of €243.4M impacting its December 31 2020 financial results.

Growing Profit Margin: BNTX became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: BNTX has become profitable over the past 5 years.

Accelerating Growth: BNTX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BNTX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).


Return on Equity

High ROE: BNTX's Return on Equity (1.1%) is considered low.


Financial Health

How is BioNTech's financial position?


Financial Position Analysis

Short Term Liabilities: BNTX's short term assets (€1.7B) exceed its short term liabilities (€606.0M).

Long Term Liabilities: BNTX's short term assets (€1.7B) exceed its long term liabilities (€340.8M).


Debt to Equity History and Analysis

Debt Level: BNTX's debt to equity ratio (11.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if BNTX's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: BNTX's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if BNTX's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is BioNTech current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BNTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BNTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BNTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BNTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BNTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

9.9yrs

Average management tenure


CEO

Ugur Sahin (54 yo)

13.25yrs

Tenure

€16,517,000

Compensation

Prof. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board. Prof. Sahin co-Founded Ganymed Pharmaceuticals AG. Prof. Sahin al...


CEO Compensation Analysis

Compensation vs Market: Ugur's total compensation ($USD19.71M) is above average for companies of similar size in the US market ($USD10.98M).

Compensation vs Earnings: Ugur's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BNTX's management team is seasoned and experienced (9.9 years average tenure).


Board Members

Experienced Board: BNTX's board of directors are seasoned and experienced ( 13.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.5%.


Top Shareholders

Company Information

BioNTech SE's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioNTech SE
  • Ticker: BNTX
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$31.311b
  • Shares outstanding: 241.52m
  • Website: https://www.biontech.de

Number of Employees


Location

  • BioNTech SE
  • An der Goldgrube 12
  • Mainz
  • Rhineland-Palatinate
  • 55131
  • Germany

Listings


Biography

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/13 22:40
End of Day Share Price2021/04/13 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.